Epilepsy drug discovery has faced treatment resistance in around 30% of patients, unmanageable side effects of many anti-seizure medications, and the development of new disease models and screening technologies. While the majority of approved anti-seizure mediations are small molecules, there is growing interest in biologics and oligonucleotides to address patient need in epilepsy and related developmental and epileptic encephalopathies (DEEs).
However, drug discovery is not a straightforward process, and over 98% of neuroscience therapeutic candidates fail to reach patients. To make it to clinic, your therapeutic must be driven through drug discovery with robust data generation from translational readouts, and expert interpretation of that data at key decision-making points.
View this webinar to learn:
- How epilepsy therapeutic projects are designed with the end in mind to answer your drug discovery questions
- How our scientists generate decision-making data across the epilepsy drug discovery process
- From data examples across high-throughput screening, lead optimization and in vitro efficacy, and in vivo pharmacology
Webinar Presenters
Russell Burley, PhD
Senior Research Leader
Charles River
Artem Shatillo, MD
Research Leader
Charles River
Offered Free by: CG Life
See All Resources from: CG Life
